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Introduction
Huntington’s disease (HD) is a hereditary brain disease char-
acterized by both motor and nonmotor manifestations. Iden-
tification of the causal gene for HD, huntingtin (HTT), has 
facilitated our understanding of the molecular pathways that 
mediate disease pathology. For instance, it has been demon-
strated that structural changes of mutant HTT elicited by the 
aberrant expansion of polyglutamine (polyQ) lead to the for-
mation of oligomers or insoluble aggregates. The polyQ aggre-
gates, which can recruit various HTT binding partners, impair 
axonal transport and damage medium spiny neurons, resulting 
in motor dysfunction in HD (1–7). HD is also characterized by 
nonmotor dysfunctions including depression (8). Nonetheless, 
the molecular mechanisms underlying such mental manifesta-
tions in HD have not been well studied.
One of the leading mediators for cellular signaling involving 
higher brain functions is cyclic 3′5′-adenosine monophosphate 
(cAMP) (9–11). cAMP levels are decreased in cerebrospinal fluid 
from HD patients and in brains from the HttQ111 knock-in mouse 
model for HD, which recapitulates the HD polyQ expansion in 
the murine Htt gene (12, 13). cAMP is degraded by various phos-
phodiesterases, of which members of the phosphodiesterase 4 
(PDE4) family play a major role, including underpinning com-
partmentalized cAMP signaling in cells (14). Active site-directed 
small-molecule inhibitors specific for PDE4, such as rolipram, 
together with targeted gene knockout and genetic studies, have 
shown that PDE4 regulates a wide range of brain functions — in 
particular, mental states such as depression and anxiety (15–19). 
The activity of PDE4 is physiologically regulated at various 
levels, including intracellular localization, protein interaction, 
and posttranslational modifications (14, 19). One of the critical 
direct interactors with PDE4 is the scaffold protein DISC1 (17, 20–
23). Physiological roles for DISC1 in biological pathways in brain 
development and neurosignaling have been intensively studied 
for the past decade in various animal models (24–26). Yet the sig-
nificance of the DISC1-PDE4 interaction in pathological contexts 
is poorly understood. Identification of a DISC1-PDE4 complex 
in conjunction with dysregulation of cAMP in HD would suggest 
the possibility that HTT might be involved in the DISC1-PDE4 
pathway, but this mechanistic link has not been examined to date. 
Furthermore, DISC1 was previously shown to form insoluble 
aggregates (27–30), but the structural basis of DISC1 aggregation 
and its neuropathological effects have not been well investigat-
ed. Here we address a novel molecular mechanism involving the 
disturbance of DISC1-PDE4 interactions and behavioral changes 
through aggregation of DISC1 in HD.
Results
Augmentation of PDE4 activity in R6/2 mice representing the polyQ 
pathology of HD. The R6/2 mouse model, which expresses the 
HD-associated human HTT mutant and represents the polyQ 
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respectively). The HTT513 and DISC1 interaction was augment-
ed more than 2-fold when polyQ was expanded (Figure 1D). The 
increased binding was also observed when a shorter N-terminal frag-
ment with an equal polyQ expansion (HTT67Q82) was used together 
with DISC1 (Figure 1E). However, the binding of DISC1 with HTT513 
was greater than that with HTT67 (Supplemental Figure 4A). These 
results indicate that amino acids 1–67 of HTT are sufficient to inter-
act with DISC1, but that additional amino acids between 68 and 513 
further facilitate the interaction. The effect of expanded polyQ was 
not observed in the interaction between PDE4B and HTT513 (Sup-
plemental Figure 4B), implying that the polyQ expansion has unique 
pathophysiological effects on the HTT-DISC1 interaction.
Selective sequestration of DISC1 into SDS-insoluble HTT aggre-
gates in R6/2 mice and HD brains. One of the hallmarks of HD is 
the formation of SDS-resistant aggregates/inclusions of mutant 
HTT with expanded polyQ (42). DISC1 is also reportedly prone 
to aggregation (27, 28), but its pathophysiological significance is, 
as yet, unclear. Thus, we tested whether a pool of DISC1 could 
be detected in the SDS-resistant fraction of the brains from the 
R6/2 model, as well as HD patients, by using a filter trap assay. 
Significant increases in the levels of DISC1 in the SDS-resistant 
fractions from the cerebral cortex and striatum of R6/2 mice were 
observed, compared with those of normal mice (Figure 2A). Simi-
lar results were observed in the SDS-insoluble fractions from HD 
patients compared with those from normal controls (Figure 2B). 
In contrast, we did not find PDE4B immunoreactivity in the SDS- 
resistant fractions of any brain samples. Furthermore, by West-
ern blotting, we observed immunoreactivity of DISC1, but not of 
PDE4B, on the top of the gel when we applied brain homogenates 
from R6/2 mice (Supplemental Figure 5A), further supporting the 
notion that a pool of DISC1 is insoluble to SDS in the R6/2 brain.
To test whether this insoluble DISC1 is associated with mutant 
HTT aggregation, we examined immunofluorescent tissue stain-
ing. We found that high-intensity DISC1 staining was colocalized 
with intranuclear aggregates of mutant HTT in both the cerebral 
cortex and striatum of R6/2 mice (Figure 2C). DISC1 is reportedly 
localized in both cytosol and nucleus (43–46). Therefore it is like-
ly that the nuclear localization of DISC1 would contribute to the 
sequestration into intranuclear HTT aggregates. Furthermore, 
colocalization of DISC1 in the HTT aggregates was also observed 
in the sections from the cortex and striatum of HD patients (Figure 
2D). In contrast, no colocalization of PDE4B in HTT aggregates 
was detected in R6/2 mouse brains (Supplemental Figure 5B).
Cross-seeding between intrinsically aggregation-prone DISC1 and 
polyQ-expanded mutant HTT. The above results suggested that 
pathologically enhanced interaction of DISC1 and mutant HTT 
may selectively facilitate the sequestration of DISC1 into the HTT 
aggregates. Therefore, we set out to evaluate possible biophysical 
mechanisms underlying the selective aggregation of DISC1 in HD. 
First, we aimed to reveal structural and physical properties of full-
length DISC1 aggregates, which have not yet been fully character-
ized even though DISC1 has been shown to be aggregation-prone 
in nature (27, 28). We performed multiple biophysical assays in 
the cell-free in vitro system and found that DISC1 spontaneously 
formed aggregates, which reacted to an amyloid-specific dye, thio-
flavin T, at a level comparable to that seen with the typical amy-
loid, HTT67Q42 (ref. 42 and Figure 3A). The fibrillar morphology 
pathology of HD, shows that HTT aggregation begins at 3.5 and 
4.5 weeks in the cerebral cortex and striatum, respectively, and is 
clearly detectable at 7 weeks and progressively continues (31). In 
this model, we first measured PDE4 activity at 4, 8, and 12 weeks. 
Intriguingly, we observed a profound augmentation of PDE4 activ-
ity in both the cerebral cortex and striatum at 8 weeks (Figure 1A). 
The elevated PDE4 activity was also observed at up to 12 weeks of 
age, but the increase in PDE4 activity in the cerebral cortex was 
reduced over time (Figure 1A). This reduction over time in the 
cerebral cortex may be due to the neuronal cell death in the cor-
tex preceding that in the striatum of R6/2 mice (31). The increased 
PDE4 activity may provide an explanation why rolipram has bene-
ficial effects in the R6/2 model (32, 33). Consistent with our novel 
discovery in vivo, when we evaluated a neuro2a cell model that 
stably expresses an N-terminal 1–67 amino acid fragment (cor-
responding to exon 1) of Htt with expanded polyQ (HTT67Q150) 
(34), we found that PDE4 activity was increased more than 3-fold 
(Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI85594DS1). In our 
assay we used pan-PDE4-selective rolipram (10 μM) at a concen-
tration known to suppress all PDE4 subtypes (35–37).
Regulation of PDE4 activity by an HTT-DISC1-PDE4 ternary 
protein complex. DISC1 interacts with dynactin (p150glued), nucle-
ar receptor corepressor (N-CoR), pericentriolar material 1 protein 
(PCM1), and kalirin-7, all of which also reportedly interact with 
huntingtin-associated protein 1 (HAP1) and/or HTT (24–26). 
The frequency of common binding partners of DISC1 and HTT 
implied that these 2 proteins may interact either directly or indi-
rectly. A recent bioinformatic approach also resulted in a similar 
proposal (38). As DISC1 and PDE4 proteins interact physically 
and functionally (17, 20, 39), we hypothesized that DISC1-PDE4, 
PDE4-HTT, and HTT-DISC1 proteins might interact. To evaluate 
this hypothesis, we conducted coimmunoprecipitation with the 
homogenates of whole mouse brains and identified the DISC1-
PDE4, PDE4-HTT, and HTT-DISC1 protein interactions (Figure 
1B and Supplemental Figure 2). The DISC1-HTT and DISC1-PDE4 
binding was more significant in striatum and cerebral cortex than 
in cerebellum (Supplemental Figure 3A).
Next, we asked whether these 3 proteins might form a ternary 
complex. Indeed, sequential coimmunoprecipitation demonstrat-
ed the formation of such a ternary complex (Figure 1C). One of the 
PDE4 isoforms, PDE4B, which is relatively abundant in cerebral 
cortex and striatum interacts directly with DISC1 (20), and has 
been implicated from genetic association studies to be function-
ally important DISC1 partners (17, 40). The PDE4B gene encodes 
several distinct isoforms, of which the major ones are the PDE4B1 
and PDE4B3 long forms and the PDE4B2 short form (41). We thus 
evaluated the binding of DISC1 with each of these isoforms and 
found that they each bound to DISC1 and to HTT (Supplemental 
Figure 3, B and C).
Specific effect of polyQ expansion on the protein binding of HTT 
with DISC1. Given that PDE4, HTT, and DISC1 form a ternary protein 
complex, then how does polyQ expansion in HTT affect these pro-
tein interactions? We examined how the polyQ expansion affected 
HTT-DISC1 protein interaction by using an N-terminal 1–513 amino 
acid fragment of HTT (HTT513) with 18 residues of polyQ, or patho-
logically expanded 82 residues of polyQ (designated Q18 and Q82, 
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tion, we examined a core region of DISC1 aggregates by mass spec-
trometry. Limited proteolysis of DISC1 aggregates with proteinase 
K treatment followed by MALDI/TOF mass analysis showed a 
single major peak at 2,012.9 (m/z) in the mass spectrum, which 
identified the core of DISC1 aggregates as the region consisting of 
residues 209–227 (Figure 3C).
was observed by electron microscopy (Figure 3B). Furthermore, 
circular dichroism spectra of DISC1 aggregates showed a nega-
tive peak at 228 nm, indicating extensive β-sheet–rich structures 
(ref. 47 and Supplemental Figure 6A). These data show that DISC1 
can form fibrillar aggregates in vitro. As DISC1 does not contain 
glutamine/asparagine-rich domains that could induce aggrega-
Figure 1. PDE4 activity could be regulated by the newly identified HTT-DISC1-PDE4 ternary protein complex. (A) PDE4 activities of the homogenates 
of cerebral cortex (left) and striatum (right) in R6/2 mice were increased compared with those in WT at 8 and 12 weeks (w) of age. Data represent mean + 
SEM. *P < 0.05, **P < 0.01, ***P < 0.001; unpaired 2-tailed t test. Cortex: 4 weeks, n = 4 per group; 8 weeks, n = 5 per group; 12 weeks, n = 9 (WT), 6 (R6/2). 
Striatum: 4, 8, and 12 weeks, n = 4 per group. (B) Protein complex of HTT-DISC1-PDE4B in cerebral cortex of WT mice. Brain homogenates were immu-
noprecipitated by an anti-PDE4B (pan-PDE4B) or anti-DISC1 (mEx3) antibody or IgG control, followed by immunoblotting with an anti-HTT (MAB2144), 
anti-DISC1 (m317C), or anti-PDE4B (pan-PDE4B) antibody. Representative immunoblots are shown from 3 independent sample sets. (C) Formation of 
HTT-DISC1-PDE4B tertiary protein complex in cerebral cortex of WT mice was detected with sequential coimmunoprecipitation. Brain homogenates were 
immunoprecipitated by PDE4B antibody (pan-PDE4B) (1st IP), then the immunoprecipitates were immunoprecipitated by an anti-DISC1 (mEx3) antibody 
(2nd IP), followed by immunoblotting with an anti-HTT (MAB2166), anti-DISC1 (m317C), or anti-PDE4B (pan-PDE4B) antibody. Negative control was immu-
noprecipitated by IgG. Representative immunoblots are shown from 3 independent sample sets. (D) Increased binding of HTT513 and DISC1 with expansion 
of polyQ (Q18 or Q82) in HEK293T cells by coimmunoprecipitation. Data represent mean + SEM (5 independent sample sets). *P < 0.05; 1-way ANOVA 
followed by Bonferroni post hoc corrections. (E) Increased binding of HTT67 and DISC1 with expansion of polyQ (Q18 or Q82) in HEK293T cells by coimmu-
noprecipitation. Data represent mean + SEM (3 independent sample sets). ***P < 0.001; 1-way ANOVA followed by Bonferroni post hoc corrections.
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Figure 2. DISC1, but not PDE4B, is sequestered into insoluble HTT aggregates in HD. (A) Filter trap assay with homogenates of cerebral cortex or striatum from 
12-week-old R6/2 mice showed significantly increased levels of HTT (EM48) (top) and DISC1 (m317C) (middle) but not PDE4B (pan-PDE4B) (bottom) in the SDS- 
resistant fraction, compared with those from WT mice. A negative control with rabbit secondary antibody alone is also shown (middle). Data represent mean + 
SEM. *P < 0.05, **P < 0.01; unpaired 2-tailed t test. n = 3 per group. (B) Filter trap assay with homogenates of cerebral cortex or striatum showed significantly 
increased levels of HTT (EM48) (top) and DISC1 (h316C) (middle) but not PDE4B (pan-PDE4B) (bottom) in the SDS-resistant fraction from HD patients (HD), 
compared with those from controls (Con). A negative control with rabbit secondary antibody alone is also shown (middle). Data represent mean + SEM. *P < 0.05, 
**P < 0.01; unpaired 2-tailed t test. n = 3 per group. (C) Immunostaining of frozen sections of cerebral cortex (left) or striatum (right) demonstrated that DISC1 was 
colocalized with intranuclear inclusions of mutant HTT in 12-week-old R6/2 mice. Green, HTT (EM48); red, DISC1 (m317C); blue, DAPI (the nucleus). Arrowheads 
show intranuclear inclusions. Scale bar: 10 μm. n = 3 per group. (D) Immunostaining of paraffin sections of cerebral cortex (left half) or striatum (right half) in HD 
patients (HD) and human controls (Con) was performed with anti-HTT (EM48) (green, left) and anti-DISC1 (h316C) (red) antibodies. Nucleus was stained by DAPI 
(blue). Merged images are shown on the right. Arrowheads show intranuclear inclusions. Scale bar: 10 μm. n = 3 (Con), 6 (HD).
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ing HTT513Q18 or HTT513Q82 to cell lysates in which DISC1 and 
PDE4B interact, and examined how exogenous HTT513 proteins 
impact the DISC1-PDE4B complex. The addition of HTT513Q82 
significantly reduced the amount of the preexisting DISC1-PDE4B 
complex, whereas that of HTT513Q18 did not (Figure 4C). Nota-
bly, as described above, augmented binding of HTT to DISC1 was 
observed with HTT513Q82 compared with HTT513Q18 (Figure 
1D). Thus, a relative loss of DISC1’s interaction with PDE4 is likely a 
major effect of the DISC1 sequestration into HTT aggregates due to 
the preferred binding of DISC1 with polyQ-expanded mutant HTT.
HTT-DISC1-PDE4 interactions for aberrant enhanced PDE4 activ-
ity in R6/2 mice. We propose that sequestration of DISC1 into HD 
aggregates may disturb the regulatory effects of DISC1 on PDE4, 
resulting in aberrant augmentation of PDE4 enzymatic activity, 
which contributes to HD pathology. If this scenario is correct, supple-
menting WT DISC1 might ameliorate such increase of PDE4 activity 
in the models we have studied here. As described above, the overex-
pression of HTT67Q150 in neuro2a cells, in which substantial levels 
of endogenous DISC1 were expressed (52), augmented PDE4 activ-
ity 3- to 4-fold (Supplemental Figure 1). When we exogenously over-
expressed WT DISC1 in the neuro2a cells expressing HTT67Q150, 
the aberrant augmentation of PDE4 activity was ameliorated (Sup-
plemental Figure 7A). Although these results are promising in terms 
of protecting cells against pathological PDE4 activation, we were 
curious why the beneficial effects of exogenous DISC1 were only 
partial. This may be because exogenously expressed DISC1 was also, 
at least in part, sequestered into HTT aggregates and could not fully 
regulate endogenous PDE4 activity.
We then set out to identify the region of DISC1 responsible for 
HTT binding, using a peptide array approach that has been used to 
successfully map the binding domain of DISC1 with protein inter-
actors and PDE4 with various partner proteins (19, 20). We antic-
ipated that a mutant DISC1 lacking a minimal domain for HTT 
interaction but maintaining PDE4 binding would not be seques-
tered into the HTT aggregates and thus would fully regulate PDE4 
activity. Analyses of mouse and human DISC1 led to consistent 
results conserved between the 2 species, in which amino acids 
206–220 of both mouse and human DISC1 were crucial for bind-
ing with HTT (Figure 5A). Furthermore, in agreement with these 
observations from peptide arrays, mutant mouse DISC1 lacking 
amino acids 201–228 (Δ201-228-DISC1) displayed a dramatic 
reduction in DISC1-HTT513 binding in cells, compared with that 
in WT DISC1 (Supplemental Figure 7B). On the other hand, this 
deletion showed no effect on DISC1-PDE4B2 binding, and signif-
icant effects on DISC1-PDE4B1 interactions (Supplemental Fig-
ure 7B), due to the complexity of the binding between DISC1 and 
PDE4 isoforms (20, 53). When we expressed WT DISC1 or Δ201-
228-DISC1 in neuro2a cells expressing the mutant HTT fragment, 
we observed that Δ201-228-DISC1 completely normalized aber-
rantly augmented PDE4 activity. The effect of Δ201-228-DISC1 
was greater than that of WT DISC1 (Supplemental Figure 7A).
If aggregation of DISC1 is mediating the reduced PDE4 
activity in HD brain, then the ectopic introduction of additional 
DISC1 should rescue the aberrant PDE4 activity seen in HD. 
Since our observations indicated that PDE4 activity was aug-
mented in the striatum of 8-week-old R6/2 mice (Figure 1A), 
we next introduced exogenous DISC1 into the striatum of the 
We then examined the effects of HTT aggregates on the kinet-
ics of DISC1 aggregation. DISC1 spontaneously formed aggre-
gates, but the aggregation was not evident for the initial 2 hours 
under the conditions tested. This 2-hour lag time was almost com-
pletely abolished by the addition of seeds (10% mol/mol) of DISC1 
aggregates at the initiation of the reaction, indicating that DISC1 
aggregates are self-seeding, a key feature of amyloid fibers (refs. 
48–50 and Figure 3D). More importantly, DISC1 aggregation was 
significantly accelerated with the addition of seeds of HTT67Q42 
aggregates, but not with the addition of BSA aggregates, which 
were used as a control (Figure 3D). Furthermore, we found no 
aggregation of PDE4B2 or a trigger factor tag in the presence of 
HTT67Q42 aggregate seeds (Figure 3D and Supplemental Fig-
ure 6B). The following immunoprecipitation experiments proved 
that the accelerated DISC1 aggregation by HTT67Q42 seeds was 
caused by coaggregation, but not by an increased rate of sponta-
neous DISC1 aggregation (Supplemental Figure 6C). After soluble 
DISC1 was incubated with HA-tagged HTT67Q42 amyloid seeds 
(HTT67 Q42-HA seeds; 10% mol/mol), the resulting HTT67 Q42-
HA aggregates contained DISC1, indicating that soluble DISC1 
formed coaggregates with HA-HTTQ42 seeds (Supplemental 
Figure 6B). These data reveal cross-seeding between DISC1 and 
mutant HTT, which is consistent with the marked colocalization 
of the 2 proteins in HD brains in vivo (Figure 2D).
The DISC1 aggregates that formed with seeds of HTT67Q42 
aggregates showed an increase in the peak at 1,620 cm–1 in Fourier 
transform infrared (FT-IR) spectra, indicating a greater level of inter-
molecular β-sheet structures (51), compared with the DISC1 aggre-
gates that were spontaneously formed in the absence of seeds (Fig-
ure 3E). Consistently, we found that the DISC1 aggregates seeded by 
HTT67Q42 amyloid showed the trend of the higher resistance to 2% 
SDS than spontaneously formed DISC1 aggregates (Figure 3F). The 
altered structural and physical properties of the DISC1 aggregates 
also supported the cross-seeding between DISC1 and mutant HTT.
Reduced DISC1-PDE4 complex by decreased soluble DISC1 levels 
in R6/2 mice. We then asked whether the physiological disposition 
of DISC1 might be impaired because of the selective sequestration 
of this protein into the HTT aggregates in HD pathology. First, we 
used sedimentation analysis with homogenates of the cerebral 
cortex and striatum, and observed that the level of soluble DISC1, 
but not that of PDE4B, was reduced in R6/2 mice compared with 
WT mice (Figure 4A). DISC1 interacts with PDE4B in soluble frac-
tions and regulates the enzymatic activity of PDE4 (17, 39). Thus, 
reduction in the levels of soluble DISC1 may result in a decrease in 
the amount of DISC1-PDE4 complex and an increase in the PDE4 
activity. Compared with substantial changes of DISC1 in the sol-
uble fractions (detected by Western blotting in Figure 4A) and 
alteration in PDE4 activity (Figure 1A), the integration of DISC1 
staining in the HTT aggregates was more modest (Figure 2, C and 
D). A portion of, but not entire, insoluble DISC1 with HTT might 
be visualized as colocalization with large HTT aggregates, since 
insoluble DISC1 with HTT microaggregates could be diffusible. In 
mouse brain homogenates, we showed a significant reduction in 
the amount of DISC1-PDE4 complex in R6/2 compared with that 
in WT mice (Figure 4B). Furthermore, we addressed whether the 
reduction of DISC1-PDE4B complex was elicited directly by the 
presence of mutant HTT. We added lysates of cells overexpress-
Downloaded from http://www.jci.org on May 22, 2017.   https://doi.org/10.1172/JCI85594
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 4 4 3jci.org   Volume 127   Number 4   April 2017
2-week-old mice by stereotaxic injection of a lentiviral vec-
tor of DISC1 connected with a GFP Venus via IRES (DISC1/
Venus). We then collected the DISC1/Venus–expressing 
cells from the striatum of the mice at 8 weeks by flow cytometry 
and measured PDE4 activity. Expression of WT DISC1 signifi-
cantly decreased the aberrant PDE4 activity in R6/2 mice (Fig-
ure 5B). Introduction of Δ201-228-DISC1 led to an even greater 
effect, which is consistent with the observations from the cell 
model (Figure 5B). These results support the notion that patho-
logical augmentation of PDE4 activity in HD pathology may be 
predominantly mediated by the partial loss of DISC1 that regu-
lates PDE4 activity. This process is determined by the seques-
tration of DISC1 from the HTT-DISC1-PDE4 ternary complex 
as a result of specifically preferred binding and coaggregation 
between mutant HTT and DISC1.
Significance of HTT-DISC1-PDE4 interactions for nonmo-
tor function in R6/2 mice. Next, we examined the in vivo conse-
quences of the disturbed DISC1-PDE4 interaction. We generat-
ed adeno-associated virus (AAV) encoding an N-terminal 1–316 
amino acid fragment of mouse DISC1, which includes most of 
the binding sites for PDE4 but lacks the binding region for HTT 
(Δ201-228-nDISC1) (Supplemental Figure 8). We stereotaxically 
injected AAV encoding control EGFP or Δ201-228-nDISC1 that 
could interact with PDE4B isoforms but not HTT, into the stri-
atum of 3-week-old R6/2 mice. Immunohistological studies 
revealed that exogenous expression of Δ201-228-nDISC1 has no 
effect on HTT aggregation and neuronal viability (Figure 5, C and 
D). We then investigated motor and nonmotor behaviors of the 
mice. We confirmed impairment of motor functions in R6/2, evi-
dent by deficits in rotarod performance and shorter distance in 
open field test, which were not altered by exogenous expression 
of Δ201-228-nDISC1 (Figure 5E and Supplemental Figure 9A). 
Next, we performed a variety of behavioral tests for nonmotor 
functions, including light/dark transition, marble burying, nest-
ing, and sucrose preference. Interestingly, in the sucrose pref-
erence test, the exogenous expression of Δ201-228-nDISC1, but 
Figure 3. Aggregation of intrinsically aggregation-prone DISC1 is accelerated by cross-seeding with polyQ-expanded mutant HTT. (A) Thioflavin T (ThT) 
fluorescent intensities of spontaneous DISC1 and HTT67Q42 aggregates were significantly higher than those of BSA aggregates. Data represent mean 
+ SEM (4 independent sample sets). ***P < 0.001; 1-way ANOVA followed by Bonferroni post hoc corrections. (B) Fibrillar morphology of typical DISC1 
aggregates shown by transmission electron microscopy. Scale bar: 100 nm. A representative image is shown from 3 independent samples. (C) MALDI-TOF 
mass spectrum of DISC1 aggregates digested by proteinase K identified a major mass peak at 2,012.9 m/z corresponding to residues 209–227 in DISC1 
as the core of DISC1 aggregates. Representative data are shown from 3 independent samples. (D) Aggregation of DISC1, which was monitored by the absor-
bance (turbidity) at 405 nm, was significantly accelerated by the HTT67Q42 aggregate seeds but not by BSA aggregates. No aggregation of PDE4B2 was 
observed in the presence of HTT67Q42 aggregate seeds. Representative data are shown from 3 independent sample sets. (E) FT-IR spectra revealed that 
the DISC1 aggregates formed in the presence of HTT67Q42 aggregate seeds (gray) contained more intermolecular β-sheet structures (arrowheads) than 
did spontaneously formed DISC1 aggregates (black). Representative data are shown from 4 independent sample sets. (F) The DISC1 aggregates formed in 
the presence of HTT67Q42 aggregate seeds showed higher resistance to 2% SDS than spontaneously formed DISC1 aggregates in the filter trap assay with 
Sypro Ruby staining. The asterisk indicates that 10% of the signal intensity of HTT67Q42 amyloid is subtracted from that of DISC1-HTTQ42 coaggregates 
for correction of the signal intensity. Data represent mean + SEM (4 independent sample sets). One-way ANOVA was used for statistical analysis.
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not expression of a control protein EGFP, significantly restored 
the reduced preference of R6/2 mice (Figure 5F). In contrast, in 
marble burying and nesting test, although the deficits existed in 
the R6/2 mice, the rescue by Δ201-228-nDISC1 was not observed 
(Supplemental Figure 9, B and C). Note that the R6/2 mice did 
not show even alterations in light/dark transition and center time 
in open field test (Supplemental Figure 9, D and E). These results 
suggest that the DISC1/PDE4/HTT pathway may be involved in a 
specific subset of nonmotor behaviors in R6/2 mice.
Discussion
Here we demonstrate that the sequestration of intrinsically 
aggregation-prone DISC1, but not PDE4, into mutant HTT 
aggregates disturbed the proper formation of an HTT-DISC1-
PDE4 ternary protein complex. This generates a PDE4 frac-
tion out of physiological control by DISC1, thereby aberrantly 
increasing PDE4 activity. Furthermore, our exploratory study 
in vivo suggests that this molecular pathway may underlie 
anhedonia in the R6/2 model (Supplemental Figure 10). Our 
Figure 4. The amount of DISC1-PDE4 
complex was reduced by decreased 
soluble DISC1 levels in R6/2 mice. (A) 
Soluble DISC1 but not soluble PDE4B 
levels in supernatant fractions (Sup) 
were reduced in cerebral cortex (top) 
and striatum (bottom) from 12-week-
old R6/2 mice, compared with those 
from WT mice. Total DISC1 and PDE4B 
levels in total homogenates (Total) 
were not changed between WT and 
R6/2 mice. β-Actin is a loading con-
trol. An m317C anti-DISC1 antibody 
was used to detect DISC1, and a neg-
ative control with rabbit secondary 
antibody alone is also shown. Data 
represent mean + SEM. **P < 0.01, 
***P < 0.001; unpaired 2-tailed t test. 
n = 3 per group. (B) The amount of 
DISC1-PDE4B complex in 12-week-old 
R6/2 mouse brains was decreased 
compared with that in WT brains. 
Immunoprecipitation was performed 
by an anti–pan-PDE4B antibody, 
followed by immunoblotting with 
anti-DISC1 antibody (D27). GAPDH is a 
loading control and used for normal-
ization of the IP data. Data represent 
mean + SEM. **P < 0.01; unpaired 
2-tailed t test. n = 5 per group. (C) 
Exogenous addition of HTT513Q82, 
but not HTT513Q18, significantly 
reduced DISC1-PDE4B interactions 
in HEK293T cells. Lysates of the 
cells overexpressing GFP alone (–), 
HTT513Q18-GFP (Q18), or HTT513Q82-
GFP (Q82) were added to lysates of 
the cells overexpressing DISC1-Myc 
and PDE4B1-HA. Mixtures were 
processed for immunoprecipitation 
with an anti–c-Myc antibody, followed 
by immunoblotting. Data represent 
mean + SEM (3 independent sample 
sets). *P < 0.05, **P < 0.01; unpaired 
2-tailed t test.
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Rolipram administration restored motor dysfunction and 
decreased both HTT aggregation and neuronal death in R6/2 mice 
(31–33), while we found that Δ201-228-nDISC1 did not affect them 
(Figure 5, C–E, and Supplemental Figure 9A). These contrasting 
results underscore that the molecular mechanisms underlying 
rolipram challenge and ectopic Δ201-228-nDISC1 expression are 
different. In contrast to the fact that rolipram could target diverse 
PDE4s (36), Δ201-228-nDISC1 would have specific inhibitory 
effects on the DISC1-associated PDE4 activity.
present study uniquely addresses mental manifestation in HD, 
compared with many previous studies in which coaggregation 
of mutant HTT with other aggregation-prone proteins was 
demonstrated to be involved in motor dysfunctions (54–56). 
Thus, we propose that this mechanism involving the HTT-
DISC1-PDE4 ternary protein complex provides a novel molecu-
lar basis for the pathology and potentially the psychiatric symp-
toms underpinning the reduced cAMP levels observed in both 
HD patients and model mice (12, 13).
Figure 5. Aberrantly enhanced PDE4 activity and reduced sucrose preference in R6/2 mice are recovered by exogenous DISC1 expression. (A) The 25-mer 
peptides #40–#42 (residues 194–228 for mouse DISC1 [left], residues 196–230 for human DISC1 [right]) in DISC1 showed binding to maltose-binding protein 
(MBP)–HTT513Q18 (bottom) but not MBP alone (top) on peptide array. A black line corresponds to the core region of aggregates, which was identified by 
limited proteolysis and mass spectrometry (see Figure 3C). Representative data are shown from 3 and 2 independent samples for mouse and human DISC1, 
respectively. (B) Aberrant augmentation of PDE4 activity in striatum of R6/2 mice was normalized with WT or Δ201-228-DISC1. Data represent mean + SEM. 
*P < 0.05, **P < 0.01; 1-way ANOVA followed by Bonferroni post hoc corrections. n = 6, 3, 3, and 3 for WT, R6/2 + Control, R6/2 + WT-DISC1, and R6/2 + Δ201-
228-DISC1 mice, respectively. (C) The number of cells with EM48-positive HTT aggregates was not affected by expression of Δ201-228-nDISC1 in striatum of 
mice at 12 weeks. Data represent mean + SEM. Unpaired 2-tailed t test was used for statistical analysis. n = 3 per group. (D) The number of NeuN-positive 
neurons was not affected by expression of Δ201-228-nDISC1 in striatum of mice at 12 weeks. Data represent mean + SEM. *P < 0.05, ***P < 0.001; 1-way 
ANOVA followed by Bonferroni post hoc corrections. n = 4, 4, 6, and 5 for WT + EGFP, WT + Δ201-228-nDISC1, R6/2 + EGFP, and R6/2 + Δ201-228-nDISC1 mice, 
respectively. (E) The impairment of motor function of R6/2 mice was not rescued by expression of Δ201-228-nDISC1. The latency to fall off the rotarod was 
examined in mice at 9 weeks. Data represent mean ± SEM. ***P < 0.001; 1-way ANOVA followed by Bonferroni post hoc corrections. n = 17, 16, 8, and 8 for WT 
+ EGFP, WT + Δ201-228-nDISC1, R6/2 + EGFP, and R6/2 + Δ201-228-nDISC1 mice, respectively. (F) Reduced sucrose preference in R6/2 mice was rescued by 
expression of Δ201-228-nDISC1. The sucrose intake was measured in mice at 9 weeks. Data represent mean + SEM. ***P < 0.001; 1-way ANOVA followed by 
Bonferroni post hoc corrections. n = 17, 16, 17, and 20 mice for WT + EGFP, WT + Δ201-228-nDISC1, R6/2 + EGFP, and R6/2 + Δ201-228-nDISC1 mice, respectively.
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raised against the purified proteins of residues 317–852 in mouse DISC1 
and residues 316–854 in human DISC1, respectively, in the Research 
Resources Center at RIKEN Brain Science Institute (Supplemental Fig-
ure 2). A mouse monoclonal antibody against  mouse DISC1 (M49) was 
produced with the purified protein of residues 317–852 as an antigen 
(MBL) (Supplemental Figure 2). For validation of mouse DISC1 anti-
bodies, Disc1 locus impairment (Disc1 LI) mice, in which a major full-
length 100-kDa isoform is depleted (59, 60), were used (Supplemen-
tal Figure 2). The following commercial or published antibodies were 
also used: mouse monoclonal antibodies against HA, Myc, and GFP 
tags (Nacalai Tesque), against mouse DISC1 (2B3) (59), and against 
β-actin (Abcam); rabbit polyclonal antibodies against HA, Myc, and 
GFP tags (MBL), against mouse DISC1 (mEx3, refs. 59–63; and D27, 
refs. 63–66), against human DISC1 (14F2) (57), and against HTT (EM48 
and MAB2144) (Millipore); and a sheep polyclonal anti–pan-PDE4B 
antibody (41). Mouse, rabbit, or sheep IgG (Santa Cruz Biotechnology) 
was also used as a control in coimmunoprecipitation experiments.
R6/2 mice
Heterozygous HTT67 (corresponding to HTT exon 1) transgenic R6/2 
mice were obtained from Jackson Laboratory and maintained by 
ovarian transplantation of female R6/2 mice carrying about 130 CAG 
repeats. R6/2 transgenic and age-matched WT mice were anesthe-
tized and the brains were removed, followed by separation of cerebral 
cortex and striatum. For measurement of PDE4 activity, storage of 
brains at –80°C was minimized.
Autopsied brains from HD patients
Autopsied brains (12–32 hours postmortem interval) from 6 HD patients 
and 3 controls at the age of 37–76 were obtained from Harvard Brain Tis-
sue Resource Center. Frozen and fixed paraffin blocks for cerebral cor-
tex and striatum include the regions from frontal cortex and caudate/
putamen/accumbens, respectively.
Measurement of PDE4 activity
PDE4 activity was assayed by our reported protocol (67). Briefly, 
brains or cells were homogenized in KHEM buffer (50 mM KCl, 10 
mM EGTA, 1.92 mM MgCl2, 1 mM DTT, and 50 mM HEPES, pH 7.2) 
containing protease inhibitor cocktail (Roche Applied Sciences) and 
centrifuged, and the supernatant fraction was used to measure the 
PDE4 activity. Total cAMP-specific phosphodiesterase activity was 
measured with 1 μM/l cAMP substrate concentration using a fluo-
rescence polarization assay (Molecular Devices) under linear condi-
tions with and without the PDE4 inhibitor rolipram at a concentration 
known to fully and selectively inhibit PDE4 (10 μM) (35).
Western blotting
A standard protocol was used, including 5%–20% gradient acrylamide 
gels (ATTO). For detection, appropriate peroxidase-conjugated second-
ary antibodies (GE Healthcare) were used in conjunction with a Super-
Signal West Pico or Femto chemiluminescent substrate (Thermo Fisher 
Scientific) to obtain images with LAS-3000 Imager (GE Healthcare).
Immunoprecipitation
Typically, cells or brains were lysed with RIPA buffer (50 mM Tris, pH 
7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
and a protease inhibitor cocktail [Roche]). Lysates were sonicated, cell 
We show here that the aggregation of DISC1 is significantly 
accelerated by the presence of mutant HTT seeds. Importantly, 
our structural analysis of DISC1 aggregates provided mechanis-
tic insights into the efficient cross-seeding between mutant HTT 
and DISC1: the core region (residues 209–227) of DISC1 aggre-
gates included the binding site for HTT (residues 206–220). 
This overlap might increase the chance of interactions between 
aggregation-prone core regions in distinct DISC1 molecules and 
thereby facilitate the sequestration of DISC1 into mutant HTT 
aggregates. In addition, the increased β-sheet structures and SDS 
resistance of DISC1 aggregates by cross-seeding with mutant HTT 
may enhance the resistance to degradation and promote further 
recruitment of soluble DISC1 into mutant HTT aggregates.
This report, with a combined cell biology and biophysical 
approach that is informed by clinical observations, formulates a 
novel hypothesis that leads us to suggest 3 questions for future stud-
ies. First, it will be important to clarify whether the sequestration of 
DISC1 into misfolded protein fractions and aggregates is specific 
to HD or more generally applied to other polyQ diseases. The pres-
ent data from the R6/2 model that represents the polyQ pathology 
implies that DISC1 may also be involved in other polyQ diseases. 
Second, the next study may use a full-length HTT mouse model 
to address the influence of HTT on broader aspects of HD pathol-
ogy. Third, it is worthwhile to address how other DISC1 interact-
ing partners could be involved in the PDE4-regulating mechanism 
controlled by the HTT-DISC1-PDE4 ternary protein complex.
Recent studies have indicated that brain samples from a sub-
group of patients with schizophrenia, bipolar disorder, or depres-
sion, as well as some preclinical models for such conditions, con-
tain insoluble DISC1 and dysbindin, another protein that might be 
involved in the biology of mental functions (27, 29, 30, 57, 58). Based 
on these findings, we propose that a selective network of misfolded 
proteins that are prone to be insoluble may underlie many aspects 
of brain dysfunctions, including psychiatric manifestations.
Methods
Plasmids and antibodies
The cDNA of full-length mouse DISC1 was subcloned into a pRK5 
vector with an HA or Myc tag at the N-terminus or into a pcDNA4 vec-
tor (Invitrogen) with a mys/His6 tag at the C-terminus. The cDNA of 
full-length human PDE4B1, 4B2, or 4B3 was subcloned into a pRK5 
vector with an N-terminal HA tag. The cDNA of HTT67 or HTT513 
containing 18 or 82 glutamine repeats was inserted into a pCSII-
CMV vector that includes EGFP at the C-terminus. For production 
of lentivirus, the cDNA of full-length or mutant mouse DISC1 with a 
C-terminal HA tag was subcloned into a pCSII-CMV-IRES-Venus 
plasmid. pCSII-CMV, pCAG-HIVgp, and pCAG-VSV-G plasmids were 
provided by the RIKEN BioResource Center. For production of AAV, 
the cDNA of full-length or mutant mouse DISC1 was subcloned into a 
pAAV2 vector. For bacterial expression of DISC1 and HTT67Q42, the 
cDNA of human DISC1, HTT513Q18, and HTT67Q42 was inserted 
into pCold-TF (Takara), pMAL (New England Biolabs), and pGEX6P2 
(GE Healthcare) vectors including a His tag at the C, N, and N termi-
nus, respectively. For bacterial expression of PDE4B2, the cDNA of 
human PDE4B2 was introduced into a pET29b vector. Rabbit polyclon-
al mouse DISC1 (m317C) and human DISC1 (h316C) antibodies were 
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Preparation of recombinant proteins and aggregates
Expression and purification of HisGST-tagged HTT67Q42 were 
reported previously (47). His-tagged human PDE4B2 was expressed at 
25°C in E. coli BL21 (DE3) Rosetta and purified with Nickel agarose resin 
(GE Healthcare). DISC1 protein was expressed at 15°C in E. coli BL21 
(DE3) Rosetta as a fusion protein with a Hisx7-tag and trigger factor (TF) 
from a pCold-TF (Takara) vector and was purified with 50 mM Tris-HCl 
buffer, pH 8.0, with 1 M NaCl and 2 mM β-mercaptoethanol under the 
native condition with Nickel agarose resin (GE Healthcare). DISC1 pro-
tein was eluted with the same buffer containing 250 mM imidazole, 
concentrated, and passed through a 1000K filter (Millipore) to remove 
preexisting aggregates. Staining with Coomassie Brilliant Blue showed 
that DISC1 was more than 90% pure, and the protein concentration 
was determined at an extinction coefficient of HisTF-DISC1 (85,600 
mM–1cm–1). For aggregate formation, typically 1 ml of 5 μM protein solu-
tion with 10 units of turbo3C protease (Accelagen) to cleave the tag was 
rotated in an end-over-end manner in a 2-ml tube at 37°C (47).
Characterization of DISC1 aggregates in vitro
The physical properties of DISC1 aggregates were examined by an 
amyloid-specific fluorescent dye, thioflavin T (Sigma-Aldrich). The flu-
orescence of thioflavin T (excitation, 442 nm; emission, 483 nm) in 50 
mM Na-glycine buffer (pH 8.0) including 12.5 μM thioflavin T and 5 μM 
DISC1 aggregates was measured with a fluorescence plate reader (ARVO 
MX, PerkinElmer) (47). For morphological observation of DISC1 aggre-
gates with transmission electron microscopy (JEM 1200EX, JEOL), an 
aliquot of 2 μM DISC1 aggregates was adsorbed onto carbon-coated 
400-mesh copper grids, followed by 2% paraformaldehyde and 2% 
glutaraldehyde in 100 mM sodium phosphate buffer. The samples were 
negatively stained with 2% sodium phosphotungstic acid. Far-UV cir-
cular dichroism and FT-IR spectra of DISC1 aggregates were measured 
as described previously (47, 68). A core region in DISC1 aggregates was 
identified with a 4800 Plus MALDI-TOF/TOF Analyzer (AB SCIEX) as 
previously reported (69). The kinetics of DISC1 aggregation was mon-
itored by the absorbance (turbidity) at 405 nm, with 10 μM DISC1 or 
PDE4B2 protein in 5 mM potassium phosphate buffer containing 150 
mM sodium chloride (pH 7.4), and 2 units of turbo3C protease in the 
absence or presence of seeds of indicated aggregates (10% [mol/mol]) 
with a plate reader in a 96-well format (SpectraMax M2, Molecular 
Devices). As a control, TF was also used in the aggregation assay. The 
aggregate seeds were prepared by sonication (Branson sonifier, 15%) of 
5 μM protein aggregates for 10 seconds. The plate reader instrument agi-
tates a 96-well plate for 5 seconds every 2 minutes. A filter trap assay was 
performed with 10 μg of HTT67Q42, DISC1, or BSA aggregates using a 
cellulose acetate membrane (0.2 μm; Advantec) in the dot blot apparatus 
(Bio-Rad). After the protein was allowed to form aggregate for 2 days, the 
sample was loaded and the membrane was washed with 5 mM potassium 
phosphate buffer (pH 7.4) with 2% SDS, followed by detection of sig-
nals with Sypro Ruby staining (Bio-Rad). For immunoprecipitation 
experiments, recombinant soluble DISC1 protein was filtered with a 
300-kDa cutoff membrane (Sartorius) to remove preexisting oligomers. 
The recombinant DISC1 or BSA protein was polymerized in the pres-
ence or absence of HA-HTT67Q42 amyloid seeds (10% [mol/mol]). 
After overnight incubation, the resulting aggregates were captured by 
anti-HA beads (Invitrogen), washed with the buffer containing 0.1% 
Triton X-100, and processed for Western blotting using anti-HA 
and h316C DISC1 antibodies.
debris was cleared by centrifugation at 200 g for 3 minutes at 4°C, and the 
soluble fraction was subjected to immunoprecipitation with a primary 
antibody or an appropriate IgG control with Dynabeads Protein G (Invi-
trogen). Green fluorescent protein (GFP) or monomeric red fluorescent 
protein was used as a negative control of binding partner. For sequential 
immunoprecipitation studies, a Crosslink Magnetic IP/Co-IP Kit (Pierce) 
was used according to the manufacturer’s protocol. The first and second 
immunoprecipitations were conducted with anti-DISC1 (m317C) and 
HTT (MAB2166) antibodies, respectively. An appropriate IgG was used 
as negative control for each reaction. For competitive binding experi-
ments, lysates of the HEK293T cells overexpressing HTT513Q18-GFP 
or HTT513Q82-GFP were added to lysates of the HEK293T cells over-
expressing DISC1-Myc and PDE4B1-HA. The mixture was processed for 
immunoprecipitation with an anti–c-Myc antibody.
Sedimentation assay
Samples (0.1 g) of cerebral cortex or striatum in WT or R6/2 mice were 
homogenized with 1 ml of RIPA buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease 
inhibitor cocktail [Roche]) by a digital homogenizer at 1,500 rpm for 
15 strokes and sonicated for 10 seconds (Branson sonifier, 15%). The 
homogenates were partially cleared by centrifugation at 200 g for 3 min-
utes at 4°C, and the supernatant (total fraction) was further centrifuged 
at 16,000 g for 15 minutes at 4°C. Protein concentration of the total 
and supernatant fractions was determined by a BCA assay kit (Thermo 
Fisher), and 60 μg of protein per well of the total and supernatant frac-
tions was used for immunoblotting.
Filter trap assay
Samples (0.1 g) of cerebral cortex or striatum in WT and R6/2 mice or 
human controls and HD patients were homogenized with 1 ml of PBS 
including a protease inhibitor cocktail (Roche) by a digital homogeniz-
er at 1,500 rpm for 15 strokes and sonicated for 10 seconds (Branson 
sonifier, 15%). The homogenates were cleared by centrifugation at 
200 g for 3 minutes at 4°C, and protein concentration of the superna-
tant (total fraction) was determined by a BCA assay kit (Thermo Fisher 
Scientific). Fifty micrograms of protein per hole of the total brain 
homogenate was loaded onto a cellulose acetate membrane (0.2 μm; 
Advantec) in the dot blot apparatus (Bio-Rad), and the membrane was 
washed with 2% SDS, followed by immunoblotting. Loading of the 
same protein amounts on the membrane was confirmed by Western 
blotting of the total fractions.
Immunohistochemistry
Mouse brains were fixed with 4% buffered paraformaldehyde, mounted 
with Tissu Mount (Shirai Kogyo), and frozen by carbon dioxide. The fro-
zen brains were sectioned with a cryostat at 10 μm (Leica CM3050 S). 
Paraffin-embedded human brains were sectioned at 5 μm, followed by 
autoclaving in 10 mM citrate buffer, pH 6.0, at 121°C for 3 minutes. The 
paraffin sections were treated with TrueBlack (Biotium) for quenching 
of lipofuscin autofluorescence, and immunostaining was performed 
with a primary antibody (1:100 to 1:500), followed by Alexa Fluor 488– 
or 546–conjugated secondary antibodies (1:300) (Invitrogen). Vecta-
shield mounting medium with DAPI (Vector Laboratories) was used to 
stain the nucleus. Fluorescent images of the serial-cut frozen or paraffin 
sections were acquired with a confocal microscope TCS SP8 (Leica) or 
LSM710 (Zeiss).
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described (72). Briefly, each mouse was placed in the center of the open 
field (50[width]x50[depth]x40[height]cm) and allowed to move free-
ly for 15 minutes. Distance traveled (centimeters) and time spent (per-
cent) in the center area (30%) of the field or in the 4 corner squares of 
the 5×5 subdivisions were measured every 1 minute and analyzed by 
TimeOFCR4 (O’Hara & Co.).
Light/dark transition. The light/dark transition test was performed 
as previously described (72). Briefly, mice were individually intro-
duced into the light box, and the door of the tunnel automatically 
opened immediately after the software detected the mouse. The mice 
were then allowed to move freely in the light/dark box for 10 minutes. 
The total distance traveled, the percentage of time spent in the light 
box, the number of transitions between the light and dark boxes, and 
the duration of the first latency period before entry to the dark box 
were measured as indices. Data were collected and analyzed using 
Time LD4 (O’Hara & Co.).
Sucrose preference test. Mice were allowed to take water or 2% 
sucrose from 2 distinct bottles, and consumed water and sucrose were 
measured every day for 4 days. The positions of the 2 bottles were 
switched after 2 days. No specificity of the mice to bottle or its position 
was observed. Sucrose preference was calculated as a percentage of 
the weight of sucrose intake over the total weight of fluid intake and 
averaged over the 4 days of testing.
Marble burying test. A mouse was placed in a cage in the presence of 15 
marbles. After 20 minutes, pictures of the cages were taken, and the num-
ber of marbles buried in bedding was counted. For nesting behavior test, 
a mouse was placed in a cage in the presence of cotton square. After 48 
hours, pictures of the cages were taken, and efficiency of the nest building 
was evaluated by a score of 1 (intact) to 5 as previously reported (73).
Statistics
For analyses of 2 groups, P values were determined by unpaired 
2-tailed t test. For analyses of 3 or more groups, including all mouse 
behavioral tests, P values were determined by 1-way ANOVA fol-
lowed by Bonferroni post hoc corrections. P values of less than 0.05 
(*), less than 0.01 (**), and less than 0.001 (***) were considered to 
be statistically significant.
Study approval
All of the animal experiments were performed in compliance with rel-
evant laws and guidelines issued by RIKEN Brain Science Institute and 
Johns Hopkins University. Samples of autopsied brains were obtained 
from the Harvard Brain Tissue Resource Center at McLean Hospital in 
Belmont, Massachusetts, USA.
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Peptide array
MBP-HTT513Q18 protein was expressed at 20°C in E. coli BL21 
(DE3) Rosetta as a fusion protein with an N-terminal Hisx7 tag and 
purified as TF-DISC1. Coomassie Brilliant Blue staining showed that 
MBP-HTT513Q18 was more than 90% pure, and the protein concentra-
tion was determined by an extinction coefficient of MBP-HTT513Q18 
(37,940 mM–1cm–1). Peptide arrays of mouse and human DISC1 were gen-
erated as previously reported (20, 64, 70). One microgram of maltose- 
binding protein (MBP) alone or MBP-HTT513Q18 protein in PBS was 
overlaid to the peptide array. The array was washed with PBS, followed 
by detection as previously reported (20, 64).
Production of lentivirus and AAV, and injection into mice
HEK293T cells were transfected with a pCSII-CMV–mouse DISC1– or 
Δ201-228-DISC1-IRES-Venus plasmid together with pCAG-HIVgp and 
pCAG-VSV-G plasmids, and forskolin (Sigma-Aldrich) was added to 
the culture medium (10 μM). Purification of lentivirus was performed 
as previously reported (64), except that the lentivirus was concentrated 
with Lenti-X Concentrator (Clontech) and the pellet was resuspended 
with MACS Neurobasal media (Miltenyi Biotec) containing MACS B27 
plus (Miltenyi Biotec) and penicillin and streptomycin (Nacalai). Ste-
reotaxic injections were bilaterally placed at 0 and 1.0 mm anterior to 
the bregma, 2.0 mm lateral to the sagittal suture, and 2.0 mm below 
the skull surface in 2-week-old WT or R6/2 mice. One microliter of len-
tivirus (200 μl of lentivirus purified from 10 ml culture) was injected 
at the rate of 0.1 μl/min by a microinjector (Narishige). Immunohis-
tochemical analyses with frozen sections of the mice confirmed the 
expression of Venus and DISC1 in striatum. At 8 weeks, the striatum of 
the mice was removed, minced on ice, and treated with a Papain Dis-
section System (Worthington) to separate cells. The cells were treated 
with propidium iodide (Nacalai), and the Venus-expressing and propid-
ium iodide–negative cells were collected by flow cytometry (FACSAria, 
BD), followed by centrifugation at 1,000 g for 15 minutes at 4°C. Prepa-
ration of AAV followed a previous report (60). Stereotaxic injections of 
AAV into mice were performed as described above.
Analysis of HTT aggregates and neuronal viability in AAV-injected mice
The numbers of cells with HTT aggregates and neurons in striatum 
of AAV-injected mice were examined as previously described (71). An 
EM48 (Millipore) or NeuN (Millipore) antibody together with Vecta-
shield mounting medium with DAPI (Vector Laboratories) was used 
for immunostaining of the striatum of AAV-EGFP– or AAV-Δ201-228-
nDISC1–injected mice at 12 weeks.
Behavioral analysis of mice
Following injection of AAV in striatum, the behavioral tests were per-
formed for WT and R6/2 mice at the age of 8–9 weeks.
Rotarod performance test. A mouse was placed on a rotating rod 
(Muromachi Kikai), and the latency time for which the mouse was 
able to run on the rod was measured. The speed of rotation was 4 rpm 
on day 1 and was increased from 4 to 40 rpm over a 4-minute peri-
od and then kept at 40 rpm for another 1 minute from day 2 to day 5. 
Mice were tested in 1 trial for 2 minutes on day 1 and in 4 trials with a 
maximum time of 300 seconds (intervals between trials were 20–30 
seconds) on days 2–5. The latency time of mice on the rotating rod was 
recorded by the instrument.
Open field test. The open field test was performed as previously 
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